Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy.
暂无分享,去创建一个
Yuhua Wang | Y. Zhang | Shutao Guo | Leaf Huang | Lei Miao | Zhenghong Xu | C. M. Lin
[1] Yuhua Wang,et al. Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[2] Fan Yang,et al. Cisplatin Protects against Acute Liver Failure by Inhibiting Nuclear HMGB1 Release , 2013, International journal of molecular sciences.
[3] F. Szoka,et al. Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs. , 2013, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[4] V. Puntes,et al. Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin , 2012, PloS one.
[5] Omid C. Farokhzad,et al. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. , 2012, ACS nano.
[6] O. Farokhzad,et al. α[subscript v]β[subscript 3] Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug , 2012 .
[7] R. Jain,et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.
[8] J. Catto,et al. Molecular mechanisms of cisplatin resistance in bladder cancer , 2012, Expert review of anticancer therapy.
[9] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[10] B. Chauffert,et al. Nucleoside-lipid-based nanoparticles for cisplatin delivery. , 2011, ACS nano.
[11] Soumya Krishnamurthy,et al. Cellular Responses to Cisplatin-Induced DNA Damage , 2010, Journal of nucleic acids.
[12] Michael M. Gottesman,et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis , 2010, Proceedings of the National Academy of Sciences.
[13] A. Sancar,et al. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase , 2010, Proceedings of the National Academy of Sciences.
[14] Feng Gao,et al. RGD-conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. , 2010, Molecular pharmaceutics.
[15] Robert Langer,et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.
[16] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[17] Wolfhard Semmler,et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.
[18] I. H. Hamelers,et al. Nanocapsules: A Novel Lipid Formulation Platform for Platinum-based Anti-cancer Drugs , 2007, Journal of liposome research.
[19] R. Langer,et al. Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.
[20] Robert Langer,et al. Nanoparticle–aptamer bioconjugates for cancer targeting , 2006, Expert opinion on drug delivery.
[21] Pradeep Tyagi,et al. Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells , 2004, International journal of cancer.
[22] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[23] D. Lebwohl,et al. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. , 1998, European journal of cancer.
[24] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[25] BARNETT ROSENBERG,et al. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.
[26] Koert N. J. Burger,et al. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity , 2002, Nature Medicine.
[27] A. Adjei,et al. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Newman,et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.
[29] M. Mcgahan,et al. The determination of platinum in biological materials by electrothermal atomic absorption spectroscopy , 1987 .